MIRIKIZUMAB
Information current as at: 1 May 2025
The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.
Submission Details
- Brand name:
-
- Omvoh®
- Pharmaceutical company:
- ELI LILLY AUSTRALIA PTY LTD
- Condition/indication:
(therapeutic use) -
- Moderate to severe ulcerative colitis (MUSC)
- PBAC Submission type:
- New listing (–)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – July 2023
- Related medicines:
- --
Progress Details
-
Submission received for: - July 2023 PBAC meeting
-
Opportunity for consumer comment: - Open 29/03/2023 and close 24/05/2023 (see PBS Website)
-
PBAC meeting: - Held on 05/07/2023
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a718
Page last updated: 31 October 2024